Ann: Successful CelGro Results Presented at Key Euro Conference, page-7

A txxll basically ... they have their place, but not cluttering up my screen!

Moving on, I like the fact that OCC's sales showed some momentum growing up to $232k from $168k which is 38% QoQ increment. If they can keep that momentum up then there is an emerging catalyst there for the stock to re-rate: STRONGER EURO SALES ... that is going to be a function of securing more agents across the EU, and gaining traction with the medical profession plus success stories. 

For me, stripping out all the noise, 1Q 2019 could be the start of the long overdue rating as we should get some tangible newsflow on J&J and see how things are tracking with the FDA. 

Hence, in short, my wish list is: 1) improving Euroland sales, on expanding momentum; 2) leverage J&J connection; and 3) FDA tick ... that is enough to get the stock moving I would argue.